Repligen (RGEN) Continues Higher on Strong RG3039 Phase 1 Data
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Join SI Premium – FREE
Repligen (Nasdaq: RGEN) shares are continuing to move higher on the session Wednesday following a release earlier showing positive data from RG3039 Phase 1 as a spinal muscular atrophy (SMA) treatment. Shares are up 8 percent on the session following the release.
From the release: "The Phase 1 trial was a blinded, ascending, single dose study of RG3039 administered to 32 healthy volunteers. The study results demonstrate that RG3039 was well tolerated at all doses administered, with no serious adverse events reported."
For more color, click here.
From the release: "The Phase 1 trial was a blinded, ascending, single dose study of RG3039 administered to 32 healthy volunteers. The study results demonstrate that RG3039 was well tolerated at all doses administered, with no serious adverse events reported."
For more color, click here.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
